Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.

ABSTRACT:

Importance

In the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, agents targeting genetic tumor abnormalities are administered to patients. In the NCI-MATCH subprotocol EAY131-Y trial, patients with an AKT1 E17K-mutated metastatic tumor received the pan-AKT inhibitor capivasertib.

Objective

To assess the objective response rate (ORR) of capivasertib in patients with an AKT1 E17K-mutated tumor.

Design, setting, and participants

Between July 13, 2016, and August 10, 2017, patients in the NCI-MATCH trial were enrolled and assigned to the subprotocol EAY131-Y nonrandomized trial. Patients included adults with an AKT1 E17K-mutated metastatic tumor that had progressed with standard treatment, and these patients were assigned to receive ca

SUBMITTER: Kalinsky K 

PROVIDER: S-EPMC7774047 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature